Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.,Journal of Clinical Oncology

当前位置： X-MOL 学术 › J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2024-06-05 , DOI: 10.1200/jco.2024.42.17_suppl.lba8503
Benjamin J. Solomon ₁ , Geoffrey Liu ₂ , Enriqueta Felip ₃ , Tony S. K. Mok ₄ , Ross Andrew Soo ₅ , Julien Mazieres ₆ , Alice Tsang Shaw ₇ , Filippo de Marinis ₈ , Yasushi Goto ₉ , Yi-Long Wu ₁₀ , Dong-Wan Kim ₁₁ , Jean-Francois Martini ₁₂ , Rossella Messina ₁₃ , Jolanda Paolini ₁₃ , Anna Polli ₁₃ , Despina Thomaidou ₁₄ , Francesca Toffalorio ₁₃ , Todd Michael Bauer ₁₅

Affiliation

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Princess Margaret Cancer Centre, Toronto, ON, Canada
Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain
State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong, China
National University Cancer Institute, Singapore, Singapore
Toulouse University Hospital, Toulouse, France
Massachusetts General Hospital Cancer Center, Boston, MA
European Institute of Oncology IRCCS, Milan, Italy
National Cancer Center Hospital, Tokyo, Japan
Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangdong, China
Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea
Pfizer Inc., La Jolla, CA
Pfizer, Milan, Italy
Pfizer Inc., Athens, Greece
Tennessee Oncology, Nashville, TN